Update on biologic and small molecules treatments in pediatric allergic diseases

医学 杜皮鲁玛 嗜酸性食管炎 美波利祖马布 特应性皮炎 奥马佐单抗 苯拉唑马布 哮喘 免疫学 过敏 过敏性哮喘 临床试验 鼻息肉 贾纳斯激酶 不利影响 过敏性炎症 内型 免疫失调 疾病 生物制剂 英夫利昔单抗 皮肤病科 斯科拉德 鼻窦炎 免疫系统 免疫球蛋白E 食物过敏 氮芥 非过敏性鼻炎 丝状蛋白 单克隆
作者
Herman T. den Dekker,Amandine Divaret‐Chauveau,Benoit Sterling,Stéphanie Coopman,R. Sharon Chinthrajah,Stéphanie Lejeune,Dorothea Holter,Thomas Eiwegger,S. Mallet,Marielle W. H. Pijnenburg,A. Deschildre
出处
期刊:Pediatric Allergy and Immunology [Wiley]
卷期号:37 (9): e70454-e70454
标识
DOI:10.1111/pai.70454
摘要

Biologics have revolutionized the treatment of severe allergic diseases in children that cannot be controlled by conventional treatments. These diseases are commonly driven by dysregulation of immune response, often driven by Type 2 pathways. By targeting them, biologics have the potential for treating one or more allergic diseases. Thus, a "treat to target" strategy is now prioritized, allowing treatment of allergic diseases in a personalized approach. The pioneer anti-IgE monoclonal antibody, omalizumab, was initially indicated for the treatment of moderate to severe allergic asthma and is now indicated for chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and food allergy (FA), highlighting the ability of biologics to target multiple allergic diseases. Other biologics have been developed in asthma and other allergic diseases, including mepolizumab (anti-IL5), benralizumab (anti-IL5 receptor), dupilumab (anti-IL-4 receptor α), and more recently tezepelumab (anti-TSLP). Clinical trials in children and/or teenagers have demonstrated their efficacy and safety, confirmed by real-life studies, in asthma, atopic dermatitis (AD), CSU, and more recently in eosinophilic esophagitis (EoE) and FA. Beyond biologics, small molecules such as Janus kinase inhibitors target other key pathways and have already been approved in AD, with ongoing clinical trials in other allergic diseases. In the pediatric specific context, these treatments raise questions, particularly regarding the choice of biologics and the goals. In the long term, the sustained efficacy, safety and impact on the natural history of allergic diseases need to be further studied. The aim of this review is to discuss the most recent data in the use of biologics and small molecules in pediatric allergic diseases and to highlight the remaining gaps in knowledge.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
健康的依白完成签到,获得积分10
刚刚
1秒前
CHEN关注了科研通微信公众号
2秒前
852的应助被迷路中恶111采纳,获得10
3秒前
3秒前
3秒前
科研通AI6.4的应助被Tuniverse_采纳,获得30
4秒前
4秒前
4秒前
4秒前
5秒前
去内蒙的小企鹅完成签到 ,获得积分10
5秒前
ubless607的应助被哒哒哒采纳,获得30
6秒前
吴洲凤发布了新的文献求助10
6秒前
whale发布了新的文献求助100
8秒前
莫小乖发布了新的文献求助50
8秒前
绪安然发布了新的文献求助10
8秒前
务实金毛完成签到 ,获得积分10
11秒前
NexusExplorer的应助被Tuniverse_采纳,获得10
11秒前
666完成签到 ,获得积分10
12秒前
科研废柴发布了新的文献求助10
12秒前
maomao发布了新的文献求助10
12秒前
重逢不太难完成签到,获得积分10
13秒前
无与伦比完成签到 ,获得积分0
14秒前
天天快乐的应助被qin202569采纳,获得10
14秒前
完美世界的应助被QiongBai520采纳,获得10
14秒前
111完成签到,获得积分10
15秒前
16秒前
16秒前
17秒前
jinhuanghuiyu完成签到,获得积分10
17秒前
可爱的函函的应助被巫凝天采纳,获得10
18秒前
爆米花的应助被初景采纳,获得10
18秒前
倪康琪完成签到,获得积分10
19秒前
笨笨迎蓉发布了新的文献求助10
19秒前
三线态乃春完成签到,获得积分10
20秒前
20秒前
GQ完成签到,获得积分10
21秒前
yqliu发布了新的文献求助10
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175336
求助须知:如何正确求助?哪些是违规求助? 9567158
关于积分的说明 21790491
捐赠科研通 7769866
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556178
邀请新用户注册赠送积分活动 2477280